Breaking News

Cangene Obtains Alzheimer’s Technology from UBC

February 22, 2013

Aims to advance an immune therapeutic treatment

Cangene has obtained commercial rights to a new technology targeting Alzheimer's Disease (AD) developed at The University of British Columbia (UBC). Following the successful research collaboration with the inventor, Dr. Neil Cashman at UBC, Cangene aims to advance an immune therapeutic treatment approach by targeting the toxic form of amyloid-beta with the potential to directly impact the disease’s mechanism of action.
"We are pleased to have the opportunity to collaborate with Dr. Cashman, who is an expert in misfolded protein diseases and help advance his ground-breaking research in Alzheimer's disease" said Dr. Laura Saward, Cangene's chief scientific officer. "While this work is in its early stages, it is showing promise for the development of a novel immunotherapy to address this devastating disease and fits Cangene's refocused strategy."
"This is an all-Canadian solution in terms of its discovery, development and advancement towards the clinic," said Dr. J.P. Heale, associate director of UBC's University-Industry Liaison Office. "The partnerships developed to advance Dr. Cashman 's outstanding research are an excellent example of how Canadian universities, funding agencies and industry partners can work together to tackle a devastating disease of national and global importance."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important